Variables affecting time to second-line therapy in 259 patients with AL amyloidosis who achieved hematologic response after up-front therapy. (A) Impact of iuFLCR at baseline on time to second-line therapy. Solid line, iuFLCR <6, 94 patients; dashed line, iuFLCR ≥6, 165 patients. P = .027. (B) Impact of up-front treatment type on time to second-line therapy. Solid line, BMDex (46 patients); dashed line, CyBorD (71 patients, P = .027 compared with BMDex); dotted line, MDex (129 patients, P = .022 compared with BMDex). (C) Impact of quality of hematologic response after up-front therapy on time to second-line therapy. Solid line, CR (82 patients, median 74 months); dashed line, VGPR (134 patients, median 44 months, P = .006 compared with CR); dotted line, PR (43 patients, median 24 months, P = .036 compared with VGPR). All the patients in PR had also achieved organ response.